In persons with T2D with inadequate glycemic control despite treatment with metformin, a reduction in plasma levels of TNFR1, interleukin 6 (IL-6), matrix metalloproteinase 7 (MMP7), and fibronectin 1 (FN1) was observed in individuals treated with canagliflozin compared to glimepiride [6]. The gene discussed is TNFRSF1A; the disease is type 2 diabetes mellitus.